Dr Michael Portman Explains How Cardiac Disease Differs Between Pediatric, Adult Patients
During an interview at the 2022 American Heart Association Scientific Sessions in Chicago, Michael A. Portman, MD, FAHA, Seattle Children's Hospital addressed how cardiac disease presents in pediatric vs adult patients.
During an interview at the 2022 American Heart Association Scientific Sessions in Chicago, the different types of cardiac diseases that present in pediatric patients vs adult patients were addressed by Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's Hospital and the University of Washington in Seattle.
Transcript
How do treatments that address cardiac disease in children differ from those given to adult patients?
That's a really good question. The first issue is that children have different types of disease than adults. So in our particular
The second population is a population of patients who have single ventricle anatomy. So instead of 2 pumping chambers of the heart, there's only 1 and you have to do a surgical procedure called a Fontan procedure to assist 1 ventricle in performing the work of both. So those patients are also at high risk for clotting.
Those patients do grow up, they all grew up to be adults, but these are different diseases than adults get, who have, for instance, atrial fibrillation or myocardial infarction or coronary artery sclerosis—they're totally different types of diseases. We do have patients who have heart failure, and that is similar to adults, but treatment for adults is not necessarily the best treatment for children.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025